撥康視雲全球創新眼科藥物CBT-001國際多中心III期臨床試驗完成全部患者入組
Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 […]
撥康視雲治療血管化瞼裂斑創新藥CBT-004在美國完成臨床II期實驗
Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The […]
撥康視雲及參天製藥宣佈就翼狀胬肉創新藥CBT-001簽訂授權協議
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium 6 August 2024 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]
